NKGen Biotech (NKGN) Stock Price

NKGen Biotech Price

NYSE·CLOSED
0.00
​
Market closed

NKGen Biotech's net margin stands at -34,745.5%, down from -5,461.3% several years earlier.

NKGen Biotech stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NKGen Biotech business model & stock analysis

NKGen Biotech Inc develops autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases using its SuperNK platform. The company commercializes SNK01 for neurodegenerative diseases and SNK02 for cancer through clinical trials. Autologous NK cell immunotherapy involves harvesting pure NK cells from patients, activating them, and reinfusing them to enhance immune function and eliminate abnormal cells. The company focuses on treating cancer and neurodegenerative conditions with its SNK platform therapies. NKGen Biotech Inc's revenue model is based on conducting clinical trials for SNK01 and SNK02, with potential future commercialization of these therapies. The company is clinical-stage, meaning it generates income through research and development funding rather than product sales. Its primary focus is on developing therapies for cancer and neurodegenerative diseases using autologous and allogeneic NK cell approaches. The company's SNK platform enables the development of therapies that use pure NK cells harvested from patients' blood, activated, and reinfused to improve immune system function. This approach targets cancer, autoimmune, and neurodegenerative diseases. NKGen Biotech Inc's business model centers on advancing these therapies through clinical trials to reach commercialization stage.

Frequently asked questions about NKGen Biotech

Converted at the current exchange rate, the NKGen Biotech share trades at 0.00 EUR (0.00 USD).

The revenue cannot currently be calculated for NKGen Biotech.

The profit cannot currently be calculated for NKGen Biotech.

The P/E ratio cannot be calculated for NKGen Biotech at the moment.

The P/S cannot be calculated for NKGen Biotech currently.

The Eulerpool Quality Score for NKGen Biotech is 3/10.

The ISIN of NKGen Biotech is US65488A1016. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of NKGen Biotech is NKGN. The ticker symbol is used to trade NKGen Biotech shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
May 21, 2021
ISIN
US65488A1016
Cusip
65488A101
Market capitalization
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.25
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
213.95 %
Last updated Nov 22, 2026, 3:48 AM

NKGen Biotech Peer Group

NKGen Biotech FIGI

NKGN:US · BBG00ZFCTT22NKGN:UA · BBG011MNM3S0NKGN:UC · BBG011MNM3T9NKGN:UN · BBG011MNM3W5NKGN:UP · BBG011MNM3X4NKGN:UQ · BBG011MNM3Y3NKGN:UB · BBG011MNM3Z2NKGN:UM · BBG011MNM417NKGN:UX · BBG011MNM426NKGN:UD · BBG011MNM471NKGN:UF · BBG011MNM4B6NKGN:VY · BBG011MNM4C5